WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009067243) MODULATION OF CD40 EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/067243    International Application No.:    PCT/US2008/012998
Publication Date: 28.05.2009 International Filing Date: 20.11.2008
IPC:
C12N 15/11 (2006.01), A61K 31/7088 (2006.01), A61P 35/00 (2006.01), A61P 29/00 (2006.01)
Applicants: ISIS PHARMACEUTICALS INC. [US/US]; 1896 Rutherford Road Carlsbad, CA 92008 (US) (For All Designated States Except US).
BENNETT, C., Frank [US/US]; (US) (For US Only).
COWSERT, Lex, M. [US/US]; (US) (For US Only).
FREIER, Susan, M. [US/US]; (US) (For US Only)
Inventors: BENNETT, C., Frank; (US).
COWSERT, Lex, M.; (US).
FREIER, Susan, M.; (US)
Agent: GINGRICH, Brenden; Knobbe Martens Olson & Bear 2040 Main Street, 14th Floor Irvine,CA 92614 (US)
Priority Data:
60/989,421 20.11.2007 US
Title (EN) MODULATION OF CD40 EXPRESSION
(FR) MODULATION DE L'EXPRESSION DE CD40
Abstract: front page image
(EN)Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
(FR)La présente invention concerne des composés antisens ainsi que des procédés permettant de réduire le CD40. Des exemples de conditions pathologiques qui peuvent être améliorées par l'administration de composés antisens ciblant le CD40 comprennent des troubles hyperprolifératifs, la maladie du greffon contre l'hôte (GVH), le rejet de greffe, l'asthme, l'hyperréactivité des voies aériennes, la maladie pulmonaire obstructive chronique (MPOC), la sclérose en plaques (SEP), le lupus érythémateux disséminé (LED) et certaines formes d'arthrite.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)